BioSpace News Archive

G1 Therapeutics, Inc., a commercial-stage oncology company, announced that it will participate in two August investor conferences.

Portage Biotech Inc., a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, announced financial results for the fiscal year ended March 31, 2023.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Pascal Touchon, President and Chief Executive Officer, will participate at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 1:00 p.m. PDT / 4:00 p.m. EDT.

AngioDynamics, Inc. (NASDAQ: ANGO) today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 9, 2023.

BioMarin Pharmaceutical Inc. announced financial results for the six months and second quarter ended June 30, 2023.

KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that the Company will report second quarter 2023 financial results on Wednesday, August 9, 2023.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 10, 2023, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2023.

Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced an update on REZZAYO™ (rezafungin for injection) which was approved by the U.S. Food and Drug Administration (FDA) earlier this year.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on July 31, 2023.

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”) today announced that an abstract with clinical trial results of its innate cell engager (ICE®) AFM24 in combination with NKGen Biotech’s SNK01 (autologous non-genetically modified NK cells), has been accepted for a poster presentation at the ASCO Breakthrough conference from 3-5 August 2023 in Yokohama, Japan.